The RECOOP HST Consortium has long-term goals to create a strategic alliance among the partner organizations, such as universities and academic institutions, signing bilateral agreements with Cedars-Sinai Medical Center. The basis for the strategic alliance is the high quality scientific output of the individual partners measured by the number of peer-reviewed journal articles, the impact factors and the citation indices. The keys for future success are the level of trust built between Cedars-Sinai and the partners, and the continuing research and innovative management capacity at each participating organization.

Gradually, the consortium will create a business model to generate income from the scientific work and related biotechnologies produced by each partner. The scientific outputs of each partner are the innovative and novel inventions that are converted into intellectual property (IP). IP has great potential to provide leeway for the biomedical industry to manufacture new diagnostic tools, to build new medical devices and to create new drugs for the benefit of the citizens of each participating country. Additionally, the protected IP has a market value, because it benefits the public. Thus, it will create income for the academic organizations and the inventors.

The consortium is looking for potential revenue sources to enable management of high quality research, which provides a basis for further innovations. With the guidance of Cedars-Sinai, the consortium will build a business plan and a new business model for science and technology (BMST). In the BMST, the partners will outline the business plan of the consortium based on the market value of the potential products that will be available from the partners.

The consortium is willing to enhance the success rate by licensing IP to the industry by building a joint patent portfolio and by creating a patent warehouse (PW). The partners realized that the creation of the PW is a realistic goal and will enhance the chances of successful licensing of the patents. The PW is targeting a niche market with a realistic opportunity to generate significant income from the licensed patents within five to seven years after its formation.

During short- and mid-term, the consortium will have some business opportunities with larger production but with a lower profit margin. Based on the background information of the partners, the consortium will have market opportunities with research and innovation management training (RIMT) capacities and research tools created by the participating partners. These tools can be placed into a research tool warehouse (RTW), packaged into research tool boxes (RTBs) and used internally to increase the research output of each participating organization. Concurrently, the RTBs can be marketed to the external (i.e., nonparticipating) research community. In the 21st century, it is common to collaborate different research groups at inter- and multidisciplinary levels. The consortium will build inter- and multidisciplinary research networks (IMRN) to enhance the competitiveness of the participating academic organizations and to attract sponsored research. A creation of a joint clinical trial management (JCTM) team can provide business opportunities in Phase III (multi-ethnic, multi-center) trials.

Globalization and rapid technological changes encourage Cedars-Sinai to build successful strategic partnerships with Central and Eastern European universities and academic organizations. It provides the opportunity of cross-fertilization among researchers of different origin. Therefore, operating collaboratively will enhance the market value of each participant.

Governing Structure of the Regional Cooperation for Health, Science and Technology
(RECOOP HST) Consortium
RECOOP HST Strategic Alliance

TheGoverning Council (GOC)
Board of Managing Directors (BMD)
Advisory Board (AB)

Patent Warehouse
The consortium member organizations will come together to build and support a fully operational patent warehouse, capable of licensing any of its technology.

Training Programs
To develop an organizational infrastructure capable of delivering at least 2 high quality regional workshops on research and innovation management each year to university faculty and administration. In addition to the workshops, develop its infrastructure so as to provide on-line (internet-based) training programs.

Research Networks
The consortium partners will identify at least 5 opportunities to collaborate on research projects funded by extramural sources.

Research Tools Warehouse
The consortium partners will jointly develop a warehouse that focuses on research tools, including: cell lines, monoclonal antibodies, animal models, growth factors, and other similar types of enabling technologies. These tools will be organized and made available to:
Consortium partners for use in further research (by 2007)
Biomedical industry for purposed licensing (by 2008)

Joint Clinical Trials Management
The consortium partners will create a single, unified group with the infrastructure capable of successfully competing for and capturing Phase 3 multi-centered clinical trials by 2007.

Strategic Planning
During the strategic planning procedure the participating organizations should answer the following questions:

The partner organizations of the Consortium have to assess where we are?
What does the Consortium need from the partners?
How can the Consortium achieve the desired results?
What will the Consortium do?
What activities should the Consortium abandon?
The Consortium has to define the next steps!

Patent Warehouse
Training Programs
Research Networks
Research Tools Warehouse
Joint Clinical Trials Management
Strategic Planning

Patent Warehouse WG

Continuous buildup of the number of invention disclosures (IDXL) based on the bilateral agreement between the partners and CSMC.

Completion of the Research Activity Inventory (RAI) at each partner (Romania, Croatia and University of Szeged)

Identification of innovative research areas at each partner organization based on the RAI

Analysis of potential innovations based on existing Material Transfer Agreements (MTA) and correlation to impact factors and citation indexes.

Initial contact with PIs of the selected research areas at each partner organization with the partner OTT

Innovation Inventory at each partner organization¿s OTT

Semiannual follow-up of the PIs with the local OTT to review the Invention Disclosure (IDXL) activities and motivate scientist to submit more disclosures.

Strengthen the broker status of Cedars with new industry contacts

Based on all the above listed activities to build the Research and Innovation Pyramid TM:

Research and Innovation Management Training

Introduction of the selected WIPO Distance Learning courses into the PhD programs and to the faculties at the partner organizations.

Creation of an annual training plan for the faculty, the PhD students and for the leadership at each partner organization.

Partner organizations have to identify if they need outside help and training support from CSMC or from the Consortium.

Research Networking

Completion of the Research Activity Inventory (RAI) at each partner (Romania, Croatia and University of Szeged).

Identification of core groups for different research networking activities based on the RAI at the Bridges in Life Sciences Annual Scientific Review Meeting.

WEB database for partner search (EU FP7 and NIH or other bilateral).

Submission of FP7 and NIH proposals based on the active core groups for different research networking.

Publication of the abstracts of the presented papers of the Bridges in Life Sciences Annual Scientific Review Meeting and their dissemination to the PIs at CSMC.

Preparing the Second Bridges in Life Sciences Annual Scientific Review Meeting in October 2008 (Dubrovnik, Croatia) and motivating CSMC PIs to present their scientific work and search for partner for research collaboration.

Joint Clinical Trial Network The Consortium will authorize two members, the University of Debrecen, Hungary and BIOVOMED of the Faculty of Military Health Sciences (FMHS), University of
Defense Hradec Kralove, Czech Republic to manage the JCTN clinical trials.

Site visit of the partner organizations and review of their Standard Operating Procedure also their compliance with all European Community directives, regulations, especially the current European Union Clinical Trial Directive EU CTD, the regulations of the European Commission for Enterprise and Industry and the guidelines of the European Medicines Agency (EMEA).

Based on the site visit JCTN will make the final list of the organizations qualified to participate in the sponsored research activities.

Primary contract negotiation with potential sponsors of Phase I ¿ III clinical trials and running of clinical trials

Research Resource Management

Research resource sharing will be a reality when the Consortium has EU funded research projects and networks.

Nevertheless the external marketing of the Research Tools could be an additional opportunity for the Consortium therefore it is necessary to complete the Research Tools Inventory.

Strategic Planning

- Examine where we are individually and how that adds up for our consortium
- Examine what the market is asking for and see if we can deliver
- Consider what we need to do, set priorities, and decide how to get it done

Human Development

Minimally Invasive Surgery

Agenda
Minutes

Agenda
Minutes

Agenda
Minutes

Agenda
Minutes